Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer

Abstract

Prostate cancer (PrCa) is characterized by progression from an androgen-dependent phenotype to one that is inevitably androgen independent (AI) and lethal. Recent evidence strongly suggests that the phosphatidylinositol-3-kinase/Akt (PI3K/Akt) and androgen receptor (AR) signalling pathways provide prostatic epithelium with the necessary signalling events to escape the apoptotic response associated with androgen withdrawal therapy. Silencing of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) and glycogen synthase kinase β (GSK3β) are frequently associated with advanced PrCa systems and likely serve critical roles in promoting AR and PI3K/Akt gain-of-function. That PTEN negatively regulates AR and is sufficient to promote metastatic PrCa in murine models strongly implies its role as a gatekeeper of progressive PrCa. In human PrCa, PTEN loss is correlated with substantial increases in AktSer473 and integrin-linked kinase expression, both of which promote Ser9 phospho-inhibition of GSK3β and inactivation of apoptotic factors. Sufficient evidence also suggests that GSK3β is not only a critical regulator of proproliferative signalling but also a promiscuous one as PI3K/Akt pools of GSK3β are, at least in part, functionally interchangeable with those of the Wnt/β-catenin pathway. Thus, GSK3β may serve not only as a mediator of PI3K/Akt activation but may also regulate the potent transactivation and proproliferative effects that Wnt3a and β-catenin confer upon AR. These data suggest that prostate-specific activation of GSK3β may serve as a viable pharmacological option. Thus, in this review, we emphasize that temporal changes in GSK3β and PTEN expression during progression to AI PrCa are important factors when considering the potential for therapies targeting the oncogenic contributions of PI3K/Akt and AR signalling pathways.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  • Altuwaijri S, Lee DK, Chuang KH, Ting HJ, Yang Z, Xu Q et al. (2004). Endocrine 25: 27–32.

  • Anna CH, Iida M, Sills RC, Devereux TR . (2003). Toxicol Appl Pharmacol 190: 135–145.

  • Asatiani E, Huang WX, Wang A, Rodriguez Ortner E, Cavalli LR, Haddad BR et al. (2005). Cancer Res 65: 1164–1173.

  • Bernard D, Pourtier-Manzanedo A, Gil J, Beach DH . (2003). J Clin Invest 112: 1724–1731.

  • Bierie B, Nozawa M, Renou JP, Shillingford JM, Morgan F, Oka T et al. (2003). Oncogene 22: 3875–3887.

  • Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE et al. (1990). Proc Natl Acad Sci USA 87: 7762–7766.

  • Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N, Sauter G et al. (2000). Cancer Res 60: 6111–6115.

  • Campbell RB, Liu F, Ross AH . (2003). J Biol Chem 278: 33617–33620.

  • Carter MD, Southwick K, Lukov G, Willardson BM, Thulin CD . (2004). J Biomol Technol 15: 257–264.

  • Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R et al. (2004a). Nat Med 10: 33–39.

  • Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D et al. (2004b). Cancer 101: 1345–1356.

  • Chesire DR, Ewing CM, Gage WR, Isaacs WB . (2002). Oncogene 21: 2679–2694.

  • Cinar B, De Benedetti A, Freeman MR . (2005). Cancer Res 65: 2547–2553.

  • Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I et al. (2003). Am J Pathol 162: 233–241.

  • Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A et al. (1994). Cancer Res 54: 5474–5478.

  • Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D et al. (1999). Cancer Res 59: 2551–2556.

  • De La Taille A, Rubin MA, Chen MW, Vacherot F, De Medina SG, Burchardt M et al. (2003). Clin Cancer Res 9: 1801–1807.

  • DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, Leander KR et al. (2005). Mol Cancer Ther 4: 271–279.

  • Ding VW, Chen RH, McCormick F . (2000). J Biol Chem 275: 32475–32481.

  • Doble BW, Woodgett JR . (2003). J Cell Sci 116: 1175–1186.

  • Downward J . (2004). Semin Cell Dev Biol 15: 177–182.

  • Dreher T, Zentgraf H, Abel U, Kappeler A, Michel MS, Bleyl U et al. (2004). Virchows Arch 444: 509–517.

  • Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R et al. (2003). Cancer Cell 4: 223–238.

  • Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D et al. (2003a). Mol Cell Biol 23: 8563–8575.

  • Fu M, Wang C, Zhang X, Pestell R . (2003b). J Steroid Biochem Mol Biol 85: 133–138.

  • Fu M, Wang C, Zhang X, Pestell RG . (2004). Biochem Pharmacol 68: 1199–1208.

  • Gao N, Zhang Z, Jiang BH, Shi X . (2003). Biochem Biophys Res Commun 310: 1124–1132.

  • Gao T, Furnari F, Newton AC . (2005). Mol Cell 18: 13–24.

  • Gingrich JR, Barrios RJ, Foster BA, Greenberg NM . (1999). Prostate Cancer Prostatic Dis 2: 70–75.

  • Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD et al. (2002). J Biol Chem 277: 29304–29314.

  • Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J et al. (2002). Oncogene 21: 4099–4107.

  • Graff JR, Deddens JA, Konicek BW, Colligan BM, Hurst BM, Carter HW et al. (2001). Clin Cancer Res 7: 1987–1991.

  • Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S et al. (2000). J Biol Chem 275: 24500–24505.

  • Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS et al. (2001). Cancer Res 61: 4315–4319.

  • Hannigan G, Troussard AA, Dedhar S . (2005). Nat Rev Cancer 5: 51–63.

  • He WW, Sciavolino PJ, Wing J, Augustus M, Hudson P, Meissner PS et al. (1997). Genomics 43: 69–77.

  • Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, Brown TJ . (1997). Mol Cell Endocrinol 126: 59–73.

  • Hemmings BA . (1997). Science 275: 628–630.

  • Huang H, Muddiman DC, Tindall DJ . (2004). J Biol Chem 279: 13866–13877.

  • Isaacs W, Kainu T . (2001). Epidemiol Rev 23: 36–41.

  • Kalesnikoff J, Sly LM, Hughes MR, Buchse T, Rauh MJ, Cao LP et al. (2003). Rev Physiol Biochem Pharmacol 149: 87–103.

  • Kang HY, Yeh S, Fujimoto N, Chang C . (1999). J Biol Chem 274: 8570–8576.

  • Kim J, Coetzee GA . (2004). J Cell Biochem 93: 233–241.

  • Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J et al. (1997). Cancer Res 57: 314–319.

  • Koksal IT, Dirice E, Yasar D, Sanlioglu AD, Ciftcioglu A, Gulkesen KH et al. (2004). Urol Oncol 22: 307–312.

  • Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S et al. (2004). Cancer Res 64: 5232–5236.

  • Krueckl SL, Sikes RA, Edlund NM, Bell RH, Hurtado-Coll A, Fazli L et al. (2004). Cancer Res 64: 8620–8629.

  • Li H, Kim JH, Koh SS, Stallcup MR . (2004). J Biol Chem 279: 4212–4220.

  • Li P, Lee H, Guo S, Unterman TG, Jenster G, Bai W . (2003). Mol Cell Biol 23: 104–118.

  • Li P, Nicosia SV, Bai W . (2001). J Biol Chem 276: 20444–20450.

  • Liao X, Thrasher JB, Holzbeierlein J, Stanley S, Li B . (2004). Endocrinology 145: 2941–2949.

  • Lin HK, Hu YC, Lee DK, Chang C . (2004). Mol Endocrinol 10: 2409–2423.

  • Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY et al. (2003). J Biol Chem 278: 50902–50907.

  • Lin HK, Yeh S, Kang HY, Chang C . (2001). Proc Natl Acad Sci USA 98: 7200–7205.

  • Lin J, Adam RM, Santiestevan E, Freeman MR . (1999). Cancer Res 59: 2891–2897.

  • Lu S, Jenster G, Epner DE . (2000). Mol Endocrinol 14: 753–760.

  • Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M et al. (2001). Science 294: 374–380.

  • Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM et al. (2004). Nat Med 10: 594–601.

  • Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, Xue Q et al. (2003). Proc Natl Acad Sci USA 100: 7841–7846.

  • Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R et al. (2002). Clin Cancer Res 8: 1168–1171.

  • Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN et al. (2004). Mol Endocrinol 18: 2388–2401.

  • Massenkeil G, Oberhuber H, Hailemariam S, Sulser T, Diener PA, Bannwart F et al. (1994). Anticancer Res 14: 2785–2790.

  • McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD . (2004). Public Health Rep 119: 174–186.

  • McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR . (1999). Cancer Res 59: 4291–4296.

  • Meijer L, Flajolet M, Greengard P . (2004). Trends Pharmacol Sci 25: 471–480.

  • Mohler JL, Gregory CW, Ford III OH, Kim D, Weaver CM, Petrusz P et al. (2004). Clin Cancer Res 10: 440–448.

  • Mulholland DJ, Cheng H, Reid K, Rennie PS, Nelson CC . (2002). J Biol Chem 277: 17933–17943.

  • Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC . (2003). Oncogene 22: 5602–5613.

  • Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ . (2001). Endocrinology 142: 4795–4805.

  • Nan B, Snabboon T, Unni E, Yuan XJ, Whang YE, Marcelli M . (2003). J Mol Endocrinol 31: 169–183.

  • Nazareth LV, Stenoien DL, Bingman III WE, James AJ, Wu C, Zhang Y et al. (1999). Mol Endocrinol 13: 2065–2075.

  • Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M . (2001). Cancer Res 61: 6276–6280.

  • Nickerson T, Pollak M . (1999). Urology 54: 1120–1125.

  • Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM et al. (2002). J Biol Chem 277: 20702–20710.

  • Perez JJ, Corcho F, Llorens O . (2002). Curr Med Chem 9: 2209–2229.

  • Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J et al. (2000). Proc Natl Acad Sci USA 97: 3207–3212.

  • Persad S, Attwell S, Gray V, Mawji N, Deng JT, Leung D et al. (2001a). J Biol Chem 276: 27462–27469.

  • Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S . (2001b). J Cell Biol 153: 1161–1174.

  • Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP . (1994). Br J Urol 73: 390–395.

  • Qi XP, Fang L, Lin KX, Xu LG, Yan L, Li F et al. (2005). Zhonghua Nan Ke Xue 11: 34–37.

  • Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM . (2003). Mol Cell Biol 23: 6139–6149.

  • Ratliff TL . (2005). J Urol 174: 1149.

  • Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G et al. (2004). J Biol Chem 279: 19191–19200.

  • Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . (2005). Science 307: 1098–1101.

  • Sharma M, Chuang WW, Sun Z . (2002). J Biol Chem 277: 30935–30941.

  • Sharp ZD, Bartke A . (2005). J Gerontol A Biol Sci Med Sci 60: 293–300.

  • Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP . (2003a). Mol Cell Biol 23 (5): 1674–1687.

  • Song LN, Herrell R, Byers S, Shah S, Wilson EM, Gelmann EP . (2003b). Mol Cell Biol 23: 1674–1687.

  • Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Nat Genet 15: 356–362.

  • Stiles B, Groszer M, Wang S, Jiao J, Wu H . (2004). Dev Biol 273: 175–184.

  • Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R et al. (2004). Cancer Cell 5: 67–78.

  • Takemaru KI, Moon RT . (2000). J Cell Biol 149: 249–254.

  • Tan C, Cruet-Hennequart S, Troussard A, Fazli L, Costello P, Sutton K et al. (2004). Cancer Cell 5: 79–90.

  • Thompson TC, Park SH, Timme TL, Ren C, Eastham JA, Donehower LA et al. (1995). Oncogene 10: 869–879.

  • Truica CI, Byers S, Gelmann EP . (2000). Cancer Res 60: 4709–4713.

  • van der Poel HG . (2004). J Urol 172: 1333–1337.

  • van Es JH, Barker N, Clevers H . (2003). Curr Opin Genet Dev 13: 28–33.

  • Verras M, Brown J, Li X, Nusse R, Sun Z . (2004). Cancer Res 64: 8860–8866.

  • Verras M, Sun Z . (2004). Mol Endocrinol 2: 391–398.

  • Vivanco I, Sawyers CL . (2002). Nat Rev Cancer 2: 489–501.

  • Wang Q, Horiatis D, Pinski J . (2004). Int J Cancer 111: 508–513.

  • Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J et al. (2003). Cancer Cell 4: 209–221.

  • Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C, Krystal GW . (2004). Mol Cancer Ther 3: 527–535.

  • Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH et al. (2000). Cancer Res 60: 6841–6845.

  • Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T et al. (2003). Nature 423: 448–452.

  • Wisniewski D, Strife A, Swendeman S, Erdjument-Bromage H, Geromanos S, Kavanaugh WM et al. (1999). Blood 93: 2707–2720.

  • Wong HY, Burghoorn JA, Van Leeuwen M, De Ruiter PE, Schippers E, Blok LJ et al. (2004). Biochem J 383: 267–276.

  • Wu L, Birle DC, Tannock IF . (2005). Cancer Res 65: 2825–2831.

  • Wu X, Hepner K, Castelino-Prabhu S, Do D, Kaye MB, Yuan XJ et al. (2000). Proc Natl Acad Sci USA 97: 4233–4238.

  • Xin L, Ide H, Kim Y, Dubey P, Witte ON . (2003). Proc Natl Acad Sci USA 100 (Suppl 1): 11896–11903.

  • Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B et al. (2002). J Biol Chem 277: 11336–11344.

  • Yeh S, Chang C . (1996). Proc Natl Acad Sci USA 93: 5517–5521.

  • Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A . (1993). Cancer Res 53: 1304–1311.

  • Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ . (2002). Cancer Res 62: 1008–1013.

  • Zhang L, Johnson M, Le KH, Sato M, Ilagan R, Iyer M et al. (2003). Cancer Res 63: 4552–4560.

  • Zhang X, Lee C, Ng PY, Rubin M, Shabsigh A, Buttyan R . (2000). Prostate 43: 278–285.

  • Zhao H, Dupont J, Yakar S, Karas M, LeRoith D . (2004). Oncogene 23: 786–794.

  • Zhu H, Mazor M, Kawano Y, Walker MM, Leung HY, Armstrong K et al. (2004). Cancer Res 64: 7918–7926.

Download references

Acknowledgements

We thank Ingo Mellinghoff, Igor Vivanco, Bangyan Stiles, Michael Cox and Bahram Valamehr for constructive advice in writing this review.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D J Mulholland.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mulholland, D., Dedhar, S., Wu, H. et al. PTEN and GSK3β: key regulators of progression to androgen-independent prostate cancer. Oncogene 25, 329–337 (2006). https://doi.org/10.1038/sj.onc.1209020

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209020

Keywords

This article is cited by

Search

Quick links